Regeneron Pharmaceuticals, Regeneron, ESMO 2026, Libtayo, Cemiplimab, Cemiplimab-rwlc, C-POST, Cutaneous Squamous Cell Carcinoma, CSCC, Non-Small Cell Lung Cancer

TARRYTOWN, N.Y. — October 6, 2026 Regeneron Pharmaceuticals, Inc. announced that it will present new clinical research across multiple...